Biofrontera (BFRI) said Wednesday that the last patient completed the one-year follow-up visit in a phase 3 study of the use of Ameluz and RhodoLED photodynamic therapy to treat superficial basal cell carcinoma, a type of skin cancer.
The study evaluated safety and efficacy in 187 patients with at least one clinically and histologically confirmed superficial basal cell carcinomas.
The company said data from the follow-up will be included in its supplemental new drug application submission to the US Food and Drug Administration, expected in Q3.
Biofrontera shares were up nearly 12% in recent trading.
Price: 1.24, Change: +0.13, Percent Change: +11.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。